Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
FAM195A CRISPR Activation Plasmid (m): sc-426985-ACT
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- FAM195A CRISPR Activation Plasmid (m) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- FAM195A CRISPR Activation Plasmid (m) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by FAM195A CRISPR Activation Plasmid (m) and FAM195A CRISPR Activation Plasmid (m2) target distinct regulatory regions upstream of the Fam195a transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: FAM195A Antibody (D-5): sc-515147
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
FAM195A CRISPR Activation Plasmid (m) | sc-426985-ACT | 20 µg | $397.00 | |||
FAM195A CRISPR Activation Plasmid (m2) | sc-426985-ACT-2 | 20 µg | $397.00 |
Fam195a encodes the mouse protein FAM195A, a poorly characterized factor with emerging links to intracellular signaling and stress-responsive cellular programs based on conserved domain architecture and expression patterns. Available evidence suggests roles in regulating protein homeostasis and membrane-associated processes that can influence cell growth, differentiation, and adaptation to metabolic cues. Altered activity of pathways governing proteostasis and stress signaling is broadly relevant to phenotypes affecting tissue maintenance and immune or neurodevelopmental function, making Fam195a a useful locus for mechanistic studies. Because functional annotations remain limited, controlled modulation of endogenous Fam195a expression can help define downstream transcriptional networks and pathway dependencies.
FAM195A CRISPR Activation Plasmid (m) provides a targeted, non-destructive approach to upregulating endogenous Fam195a expression without altering the underlying DNA sequence.
FAM195A CRISPR Activation Plasmid (m) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the Fam195a locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the Fam195a transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous FAM195A expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native Fam195a locus and enabling the study of FAM195A-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of FAM195A pathway restoration in tumor cells with silenced or reduced Fam195a expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.